Medication info
Lokan Duo Tablets 10/16 mg

Lokan Duo Tablets 10/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Alvogen Korea Co., Ltd.
Appearance
Yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201702399 · Approved 2017.05.16 · Insurance code 652606360

Summary

Main use
Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Alvogen Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of dyslipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • decreased tolerance to ACE inhibitors
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medicine is prescribed for patients who need to use the two drugs, Candesartan Cilexetil and Rosuvastatin, together. Candesartan Cilexetil is primarily used in patients with essential hypertension and heart failure with left ventricular systolic dysfunction, especially when additional therapy to ACE inhibitors is needed or when there is poor tolerance. Rosuvastatin is used when primary hypercholesterolemia and mixed hyperlipidemia are not controlled by diet and exercise, and it is also used as an adjunct to diet in patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia. Additionally, Rosuvastatin helps lower cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis and reducing cardiovascular disease risk, thus decreasing the risk of stroke, myocardial infarction, and vascular revascularization. The combination of these two medications is effective not only in managing hypertension and heart failure but also in improving hyperlipidemia and preventing cardiovascular diseases.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. Elderly patients: No adjustment of the initial dose is necessary. Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

Essential hypertension: The safety and efficacy in adolescents and children 18 years of age or younger have not been established. Heart failure: The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Individuals with allergic reactions to this medication or with liver disease, severe liver impairment, myopathy, or severe renal impairment should not take it. Women of childbearing age should use appropriate contraceptive methods considering the possibility of pregnancy, and if planning pregnancy, should consult a doctor. Elderly patients, those with reduced liver function, or patients with hyperkalemia should use this medicine with caution, and it is important to regularly monitor liver and kidney function through blood tests. If symptoms such as muscle pain, muscle weakness, or muscle cramps occur, immediate medical attention is required, and in severe cases, the medication may need to be discontinued. This medication may increase liver enzyme levels, thus regular liver function tests are necessary, and if symptoms of liver damage appear, immediate consultation with a doctor is required. As it can lower blood pressure, caution should be exercised in cases of hypotension, dizziness, or fainting, and care should be taken while driving or operating machinery. When taken with other antihypertensives, diuretics, or potassium-sparing agents, potassium levels in the blood may increase, necessitating regular monitoring. During treatment, avoid vigorous exercise or activities that stress the muscles, and consult medical professionals immediately if muscle-related symptoms worsen. Patients with lactose intolerance should not take this medication, and due to potential drug interactions, it's essential to inform a doctor or pharmacist if taking other medications. Pregnant and breastfeeding women should not take this medication, and if breastfeeding, discussions regarding alternative medications should be held.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, orthostatic dizziness, milia, periodontitis, inflammation, foreign body sensation, chest discomfort, musculoskeletal pain, neck pain, cataract, increased blood glucose, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, nausea, abdominal pain, myalgia, myopathy, rhabdomyolysis, ALT increase, CK increase, AST increase, weakness, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, abdominal pain, diarrhea, loss of appetite, abdominal distension, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, paralysis, anxiety, facial flushing, facial edema, thirst, sleep disorders, decreased libido, forgetfulness, loss of appetite, increased appetite, tinnitus, dysgeusia, erectile dysfunction, vascular edema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnesia, memory disorder, confusion, severe muscle weakness, ocular muscle weakness, hypotension, hyperkalemia, renal function impairment, increased creatinine, increased urea, increased potassium, decreased sodium, ALT elevation, leukopenia, neutropenia, agranulocytosis, fatigue, feelings of hunger, sweating, tremors, decreased concentration, seizures, altered consciousness, pneumonia, intestinal vascular edema, jaundice, hepatitis, rash, urticaria, vascular edema, rhabdomyolysis, joint pain, myalgia, low back pain, renal function impairment, acute renal failure, interstitial pneumonia, shock, syncope, loss of consciousness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase increase, Stevens-Johnson syndrome, drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory impairment, forgetfulness, amnesia, memory disorder, confusion, severe muscle weakness, ocular muscle weakness, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medicine should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This way, the effectiveness of the medication can be preserved for a longer period.

Appearance and packaging

Appearance

Yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.